FGF19 and metabolic dysfunction-associated steatohepatitis: NGM282 is proving to be a safe and highly effective engineered FGF19 analogue in rapidly improving liver fat content and liver fibrosis in patients with NASH (NCT02443116).18 A recent randomized controlled study evaluated NASH patients who received NGM282 (1 mg, n = 24 or 3 mg n = 19) for 12 weeks.83 At week 12, 50% and 68% of the patients receiving NGM282 1 or 3 mg, respectively, improved histological NAFLD activity score by two or more points without worsening fibrosis.